JP2008525029A - 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列 - Google Patents

遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列 Download PDF

Info

Publication number
JP2008525029A
JP2008525029A JP2007548393A JP2007548393A JP2008525029A JP 2008525029 A JP2008525029 A JP 2008525029A JP 2007548393 A JP2007548393 A JP 2007548393A JP 2007548393 A JP2007548393 A JP 2007548393A JP 2008525029 A JP2008525029 A JP 2008525029A
Authority
JP
Japan
Prior art keywords
seq
promoter
sequence
stranded rna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007548393A
Other languages
English (en)
Japanese (ja)
Inventor
パチャック，キャサリン
サティシュチャンドラン，チャンドラセカール
ズラウスキ，ビンセント，ジュニア
ミンツ，リアット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucleonics Inc
Original Assignee
Nucleonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleonics Inc filed Critical Nucleonics Inc
Publication of JP2008525029A publication Critical patent/JP2008525029A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
JP2007548393A 2004-12-22 2005-12-20 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列 Pending JP2008525029A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63829404P 2004-12-22 2004-12-22
PCT/US2005/046162 WO2006069064A2 (en) 2004-12-22 2005-12-20 Conserved hbv and hcv sequences useful for gene silencing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012179638A Division JP2012223202A (ja) 2004-12-22 2012-08-13 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列

Publications (1)

Publication Number Publication Date
JP2008525029A true JP2008525029A (ja) 2008-07-17

Family

ID=36602266

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007548393A Pending JP2008525029A (ja) 2004-12-22 2005-12-20 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
JP2012179638A Pending JP2012223202A (ja) 2004-12-22 2012-08-13 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
JP2014179056A Expired - Fee Related JP5934310B2 (ja) 2004-12-22 2014-09-03 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012179638A Pending JP2012223202A (ja) 2004-12-22 2012-08-13 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
JP2014179056A Expired - Fee Related JP5934310B2 (ja) 2004-12-22 2014-09-03 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列

Country Status (7)

Country Link
EP (2) EP1833967B1 (enExample)
JP (3) JP2008525029A (enExample)
AT (1) ATE507293T1 (enExample)
AU (1) AU2005319306B9 (enExample)
CA (1) CA2592099A1 (enExample)
DE (1) DE602005027747D1 (enExample)
WO (1) WO2006069064A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503479A (ja) * 2013-11-28 2017-02-02 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
JP2020120674A (ja) * 2012-12-06 2020-08-13 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ Ｃｒｉｓｐｒに基づくゲノム修飾および制御

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
CA2824308A1 (en) * 2004-09-24 2006-04-06 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by rnai
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
US20150031571A1 (en) * 2012-02-07 2015-01-29 University Of Kansas Chemiluminescent nanoparticles and uses thereof
WO2013159109A1 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
AU2017260580B2 (en) 2016-05-05 2022-07-28 Benitec IP Holdings Inc. Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
KR20190076050A (ko) * 2016-11-11 2019-07-01 얀센 바이오파마, 인크. Hbv cccdna용 올리고뉴클레오티드 표적화 방법
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
WO2020036862A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
JP2012179638A (ja) * 2011-03-01 2012-09-20 Yamamoto Tekkosho:Kk 連続プレス装置

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995027788A1 (en) * 1994-04-11 1995-10-19 Dainabot Co., Ltd. Polypeptide derived from variant hepatitis b virus, gene encoding the same, and related dna
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5874565A (en) 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6482804B1 (en) 1997-10-28 2002-11-19 Wyeth Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP2002506801A (ja) 1998-03-16 2002-03-05 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳類の皮膚のセルライトを軽減する方法
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
WO2001038498A2 (en) * 1999-11-24 2001-05-31 Pharmasset, Ltd. A new genotype of hepatitis b virus
EP1234040A2 (en) * 1999-12-03 2002-08-28 Innogenetics N.V. Hbv sequences
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002072763A2 (en) * 2001-03-09 2002-09-19 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
JP4744874B2 (ja) 2002-05-03 2011-08-10 ハーマン インターナショナル インダストリーズ インコーポレイテッド サウンドの検出および特定システム
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
JP3839453B2 (ja) * 2002-11-22 2006-11-01 株式会社バイオシンクタンク Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004063375A1 (en) * 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
JP4545091B2 (ja) * 2003-01-24 2010-09-15 財団法人 東京都医学研究機構 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
ATE554185T1 (de) 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
DK2270162T3 (en) * 2003-06-12 2019-01-21 Alnylam Pharmaceuticals Inc PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
EP2169072A1 (en) * 2004-08-23 2010-03-31 Alnylam Pharmaceuticals, Inc Multiple RNA polymerase III promoter expression constructs
JP2015086965A (ja) 2013-10-31 2015-05-07 株式会社エクセディ フライホイール組立体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
JP2012179638A (ja) * 2011-03-01 2012-09-20 Yamamoto Tekkosho:Kk 連続プレス装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS LETT., 2004.02(ONLINE), VOL.560, P.210-214, JPN6011039008, ISSN: 0001975927 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020120674A (ja) * 2012-12-06 2020-08-13 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2022115994A (ja) * 2012-12-06 2022-08-09 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP7478772B2 (ja) 2012-12-06 2024-05-07 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2017503479A (ja) * 2013-11-28 2017-02-02 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター

Also Published As

Publication number Publication date
DE602005027747D1 (de) 2011-06-09
EP2316942B1 (en) 2021-04-21
WO2006069064A3 (en) 2007-10-25
JP2012223202A (ja) 2012-11-15
EP1833967B1 (en) 2011-04-27
AU2005319306A1 (en) 2006-06-29
WO2006069064A2 (en) 2006-06-29
AU2005319306B2 (en) 2012-01-12
CA2592099A1 (en) 2006-06-29
JP5934310B2 (ja) 2016-06-15
EP1833967A2 (en) 2007-09-19
JP2015003913A (ja) 2015-01-08
EP2316942A1 (en) 2011-05-04
ATE507293T1 (de) 2011-05-15
AU2005319306B9 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
JP5934310B2 (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
JP5593279B2 (ja) 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
KR20100060018A (ko) 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
US20150148402A1 (en) Modified small interfering rna molecules and methods of use
AU2018200873B2 (en) Conserved HBV and HCV sequences useful for gene silencing
AU2013257445B2 (en) Conserved HBV and HCV sequences useful for gene silencing
AU2012202085A1 (en) Conserved HBV and HCV sequences useful for gene silencing

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120813

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140714